Development of novel therapeutics

We are engaged in developing novel therapeutic compounds to treat drug resistant bacterial infections using a number of parallel approaches:

a) Together with Sir Mark Welland’s team at the Nanoscience Centre (University of Cambridge), we are exploring how to create nanoparticles containing antibiotics to combat M. tuberculosis and nontuberculous mycobacteria in a programme funded by The Rosetree Foundation.

b) In collaboration with Professor Sir Tom Blundell (Biochemistry; Cambridge) and Professor Chris Abell (Chemistry; Cambridge) we are using Fragment-based drug discovery approaches and developing novel structure- directed applications to develop novel antibiotics for M. abscessus.

c) We are exploring a variety of approaches to enhanced innate immunity through stimulating autophagy, increasing lysosomal function, and regulating Pattern recognition receptor signaling. 

Related publications:

Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.

Schiebler M, et al., EMBO Mol Med. 2014 Dec 22;7(2):127-39. 

PMID: 25535254

  • images
  • univ cam
  • Pubmed
  • LinkedIn Social Icon
  • Twitter Classic

© 2020  Floto Group